16:00 , Nov 16, 2018 |  BC Week In Review  |  Company News

Celgene pays Dragonfly $50M to expand NK cell immunotherapy deal

Celgene Corp. (NASDAQ:CELG) expanded its deal with Dragonfly Therapeutics Inc. (Waltham, Mass.), doubling the number of trispecific NK cell engager cancer compounds that Celgene may in-license. Under the expansion, Celgene will pay Dragonfly $50 million...
15:59 , Nov 16, 2018 |  BC Week In Review  |  Company News

Arena licenses ralinepag to United, moves S1PR1 agonist to center stage

United Therapeutics Corp. (NASDAQ:UTHR) licensed exclusive, worldwide rights to pulmonary arterial hypertension compound ralinepag from Arena Pharmaceuticals Inc. (NASDAQ:ARNA) in a Nov. 15 deal that highlights how far Arena’s come since it shifted its focus...
00:26 , Nov 16, 2018 |  BC Extra  |  Company News

Arena licenses ralinepag to United, moves S1PR1 agonist to center stage

United Therapeutics Corp. (NASDAQ:UTHR) licensed exclusive, worldwide rights to pulmonary arterial hypertension compound ralinepag from Arena Pharmaceuticals Inc. (NASDAQ:ARNA) on Thursday in a deal that highlights how far Arena’s come since it shifted its focus...
21:52 , Nov 14, 2018 |  BC Extra  |  Company News

Celgene pays Dragonfly $50M to expand NK cell immunotherapy deal

Celgene Corp. (NASDAQ:CELG) expanded its deal with Dragonfly Therapeutics Inc. (Waltham, Mass.), doubling the number of trispecific NK cell engager cancer compounds that Celgene may in-license. Under the expansion, Celgene will pay Dragonfly $50 million...
23:28 , Nov 2, 2018 |  BioCentury  |  Finance

Bye-bye, build-to-buy

As another Inception Sciences Inc. company secures an exit, Versant Ventures plans to move away from its build-to-buy model to focus on creating stand-alone companies with broader portfolios and investor syndicates. On Oct. 31, Ophthotech...
20:03 , Nov 2, 2018 |  BC Week In Review  |  Financial News

Arch to raise $600M for tenth fund

Arch Venture Partners is raising $600 million for its Arch Venture Fund X LP, according to an SEC filing. The firm declined to provide details, although the filing notes that no capital has been raised...
19:51 , Nov 2, 2018 |  BC Week In Review  |  Clinical News

BCMA race heats up as ASH abstracts released

Abstracts released ahead of next month's American Society of Hematology meeting highlighted the competition among products representing three anti-BCMA (TNF receptor superfamily member 17; TNFRSF17; CD269) modalities in development to treat multiple myeloma. On the...
19:50 , Nov 2, 2018 |  BC Week In Review  |  Clinical News

MorphoSys reports updated ORR of 58% for MOR208 in DLBCL

MorphoSys AG (Xetra:MOR; NASDAQ:MOR) reported that MOR208 plus Revlimid lenalidomide led to a 58% overall response rate (ORR) among 81 evaluable patients with relapsed or refractory diffuse large B cell lymphoma in the Phase II...
22:59 , Nov 1, 2018 |  BC Extra  |  Tools & Techniques

Selective degradation could be on horizon for imids

A...
22:55 , Nov 1, 2018 |  BC Extra  |  Clinical News

MorphoSys gains on updated response data for MOR208 in DLBCL

MorphoSys AG (Xetra:MOR; NASDAQ:MOR) shares rose Thursday when it reported that MOR208 plus Revlimid lenalidomide led to a 58% overall response rate (ORR) among 81 evaluable patients with relapsed or refractory diffuse large B cell...